Sriram
@vesriram.bsky.social
Perpetual student of science + pretending to be biotech VC
Itepekimab (Sanofi/Regeneron) and Tozorakimab (AstraZeneca) are anti-IL-33 antibodies in Phase III clinical development for COPD. Etokimab (AnaptysBio) is early in development. GSK had a license for CNTO 7160 but it targets IL-33 receptor and can’t figure out the status.
January 22, 2025 at 1:54 AM
Itepekimab (Sanofi/Regeneron) and Tozorakimab (AstraZeneca) are anti-IL-33 antibodies in Phase III clinical development for COPD. Etokimab (AnaptysBio) is early in development. GSK had a license for CNTO 7160 but it targets IL-33 receptor and can’t figure out the status.
Novartis had an inhaled antibody called Ecleralimab (CSJ117) in development but I can't find it in their pipeline anymore.
January 22, 2025 at 1:49 AM
Novartis had an inhaled antibody called Ecleralimab (CSJ117) in development but I can't find it in their pipeline anymore.
J&J acquired Proteologix to access anti-TSLP/IL-13 bispecific. Innovent has anti-TSLP/IL-4Ra bispecific (IBI3002). Teva and Sanofi/Regeneron have anti-TSLP/IL-13 bispecific programs as well.
January 22, 2025 at 1:45 AM
J&J acquired Proteologix to access anti-TSLP/IL-13 bispecific. Innovent has anti-TSLP/IL-4Ra bispecific (IBI3002). Teva and Sanofi/Regeneron have anti-TSLP/IL-13 bispecific programs as well.
Others in this space incl Perseus Therapeutics (Duke license) developing anti-TSLP for hair loss. Blackstone launched Uniquity by in-licensing Merck's anti-TSLP. GSK acquired Aiolos Bio for AIO-001 (anti-TSLP). Probably more that I missed
January 22, 2025 at 1:44 AM
Others in this space incl Perseus Therapeutics (Duke license) developing anti-TSLP for hair loss. Blackstone launched Uniquity by in-licensing Merck's anti-TSLP. GSK acquired Aiolos Bio for AIO-001 (anti-TSLP). Probably more that I missed